common.study.topics.clinical

Antidepressant Treatment for Depression

common.study.values.description

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Aripiprazole

Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.

Device - Repetitive transcranial magnetic stimulation (rTMS)

Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.

Drug - Venlafaxine XR

Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.

participant.views.study.view.additional

participant.views.study.view.scientific-title

Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)

common.study.values.clinical-trial-id

NCT02977299

participant.views.study.view.id

1aK2Me